news, events, and lectures | postdoctoral programs
predoctoral programs | faculty | university community

faculty

Miklos Sahin-Toth Associate Professor Boston Medical Center 715 Albany Street, EVANS-433 Boston, MA 02118 Telephone: (617) 414-1070 miklos@bu.edu

education

MD, Semmelweis University, Budapest, Hungary, 1988; Ph.D. Semmelweis University, Budapest, Hungary, 1994
Postdoctoral Training: Howard Hughes Medical Institute at the University of California Los Angeles, 1990-1993; The Scripps Research Institute, 1993-1995

research description

The Role of Proteases in Pancreatitis. Our laboratory studies how various proteases and their inhibitors in the pancreas contribute to the pathogenesis of pancreatitis. Pancreatitis is believed to occur due to inappropriate, intrapancreatic activation of digestive enzymes (e.g. trypsin, chymotrypsin, elastase), which are normally synthesized and stored in their inactive forms in the pancreas. Our long-term objectives are to understand the molecular mechanisms of human pancreatitis, using genetically determined pancreatitis (e.g. hereditary pancreatitis) as a biochemical model. The main focus of our research program is to provide biochemical evidence that genetic alterations in the three human trypsinogen isoforms (PRSS1, PRSS2 and PRSS3 genes) and the pancreatic secretory trypsin inhibitor (SPINK1 gene) can significantly influence the susceptibility for the development of pancreatitis. Thus, gain-of-function mutations in cationic trypsinogen can cause pancreatitis, while loss of function mutations in anionic trypsinogen can actually protect against pancreatitis. Loss of the inhibitory function of SPINK1 either due to mutations or to degradation by mesotrypsin can represent another risk factor for pancreatitis onset. The following specific projects are studied. (1) The role of human mesotrypsin in pancreatitis. Mesotrypsin is a unique protease specialized for the degradation of trypsin inhibitors. Premature mesotrypsinogen activation might lower protective SPINK1 levels in the pancreas and contribute to the pathogenesis of pancreatitis. (2) Characterization of pancreatitis-associated cationic trypsinogen (PRSS1) mutants. Identification of novel mutation-dependent biochemical defects that lead to hereditary pancreatitis (3) Functional analysis of anionic trypsinogen (PRSS2) mutants that afford protection against pancreatitis. The concept that loss-of-function trypsinogen mutations can protect against pancreatitis provides independent evidence for the central role of trypsin in this disease. (4) Identification of the disease-causing biochemical defects in pancreatitis-associated SPINK1 mutants.

representative publications

Rosendahl J, Witt H, Szmola R, Bhatia E, Ózsvári B, Landt O, Schulz H-U, Gress TM, Pfützer R, Löhr M, Kovacs P, Blüher M, Stumvoll M, Choudhuri G, Hegyi P, te Morsche RHM, Drenth JPH, Truninger K, Macek M Jr., Puhl G, Witt U, Schmidt H, Büning C, Ockenga J, Kage A, Groneberg DA, Nickel R, Berg T, Wiedenmann B, Bödeker H, Keim V, Mössner J, Teich N, Sahin-Tóth M. (2008) Chymotrypsin C (CTRC) alterations that diminish activity or secretion are associated with chronic pancreatitis. Nat Genet 40, 78-82.

Szmola R, Sahin-Tóth M. (2007) Chymotrypsin C (caldecrin) promotes degradation of human cationic trypsin: identity with Rinderknecht’s enzyme Y. Proc Natl Acad Sci USA 104, 11227-11232.

Király O, Wartmann T, Sahin-Tóth M.  (2007) Missense mutations in pancreatic secretory trypsin inhibitor (SPINK1) cause intracellular retention and degradation. Gut 56, 1434-1439.

Király O, Boulling A, Witt H, Le Maréchal C, Chen JM, Rosendahl J, Battaggia C, Wartmann T, Sahin-Tóth M, Férec C. (2007) Signal peptide variants that impair secretion of pancreatic secretory trypsin inhibitor (SPINK1) cause autosomal dominant hereditary pancreatitis. Hum Mutat 28, 469-476.

Nemoda Z, Sahin-Tóth M. (2006) Chymotrypsin C (caldecrin) stimulates autoactivation of human cationic trypsinogen. The Journal of Biological Chemistry 281, 11879-11886.

Sahin-Tóth M, Kukor Z, Nemoda Z. (2006) Human cationic trypsinogen is sulfated on Tyr154.  FEBS Journal 273, 5044-5050.

Witt H, Sahin-Tóth M, Landt O, Chen JM, Kahne T, Drenth JP, Kukor Z, Szepessy E, Halangk W, Dahm S, Rohde K, Schulz HU, Le Marechal C, Akar N, Ammann RW, Truninger K, Bargetzi M, Bhatia E, Castellani C, Cavestro GM, Cerny M, Destro-Bisol G, Spedini G, Eiberg H, Jansen JB, Koudova M, Rausova E, Macek M Jr, Malats N, Real FX, Menzel HJ, Moral P, Galavotti R, Pignatti PF, Rickards O, Spicak J, Zarnescu NO, Bock W, Gress TM, Friess H, Ockenga J, Schmidt H, Pfutzer R, Lohr M, Simon P, Weiss FU, Lerch MM, Teich N, Keim V, Berg T, Wiedenmann B, Luck W, Groneberg DA, Becker M, Keil T, Kage A, Bernardova J, Braun M, Guldner C, Halangk J, Rosendahl J, Witt U, Treiber M, Nickel R, Ferec C. (2006) A degradation-sensitive anionic trypsinogen (PRSS2) variant protects against chronic pancreatitis. Nature Genetics 38, 668-673.

Teich N, Rosendahl J, Tóth M, Mossner J, Sahin-Tóth M. (2006) Mutations of human cationic trypsinogen (PRSS1) and chronic pancreatitis.  Human Mutation 27, 721-730.

Szepessy E, Sahin-Tóth M. (2006) Human mesotrypsin exhibits restricted S1' subsite specificity with a strong preference for small polar side chains. FEBS Journal 273, 2942-2954.

Sahin-Tóth M. (2006) Biochemical models of hereditary pancreatitis. Endocrinology and Metabolism Clinics of North America 35, 303-312.